この記事の翻訳を準備しています。それまでの間、英語の原文を表示します。
ビジネス · 2016/1/151 分で読めます
How Should Liver Injury and Dysfunction Caused by Drugs Be Measured, Evaluated, and Acted Upon in Clinical Trials?
ローカル自動翻訳 · 情報源の原言語
概要
The Food and Drug Administration (FDA) is announcing a public conference entitled "How Should Liver Injury and Dysfunction Caused by Drugs Be Measured, Evaluated, and Acted Upon in Clinical Trials?" This conference will be cosponsored with the Critical Path Institute (C- Path). The purpose of the conference is to discuss, debate, and share views among stakeholders in academia, patient groups, regulatory bodies, and the health care and pharmaceutical industries on how best to measure, evaluate, and act upon liver injury and dysfunction caused by drugs used during clinical trials.
情報源の原言語: Federal Register — Food and Drug Administration原文の発表を開く →